Clinical trials: Cardiovascular Disease Acute
Atrial Fibrillation
Performance and Safety of the Globe® Mapping and Ablation System With the GPS™ Module for the Treatment of Atrial Fibrillation
This study will evaluate the safety and acute performance of the Globe® Mapping and Ablation System with the GPS™ Module intended to conduct electroanatomic mapping and ablation treatment of subjects with atrial fibrillation (AF).
- Trial name
- GPS-CA (NCT04486924)
- Testing
- Globe Mapping and Ablation System
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- Kardium Inc.
Hereditary Angioedema (HAE)
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
- Trial name
- NCT02741596
- Testing
- DX-2930
- Where
- 43 sites in United States, Canada and 5 more
- Volunteers
- 212 people
- Sponsor
- Shire
Stroke, Acute
Pilot Study of Acute Stroke Using the Brainpulse™
The aim of this pilot study is to collect data on stroke patients and non-stroke patients or healthy volunteers using the BrainPulse Stroke Monitor.
- Trial name
- NCT03235271
- Testing
- BrainPulse Device
- Where
- 3 sites in United States
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Venous Thrombosis, Deep Vein Thrombosis
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for…
- Trial name
- NCT00839163
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist
- Where
- 110 sites in Australia, Austria and 17 more
- Volunteers
- 613 people
- Sponsor
- Bayer
Acute Coronary Syndrome
Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain
The purpose of this study is to evaluate if the implementation of quantitative pretest probability assessment will significantly reduce the unnecessary use of the intra-emergency department chest pain center.
- Trial name
- NCT00243516
- Testing
- PREtest Consult
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- PREtest Consult
Aneurysm Thoracic, Dissection of Aorta, Thoracic
TBE Zone 2 PMS in Japan
The goal of this surveillance is to confirm the TBE device's safety and efficacy in patients treated with proximal landing in Zone 2 in the post-marketing period.
- Conditions
- Aneurysm Thoracic, Dissection of Aorta, Thoracic, Trauma
- Trial name
- NCT07049913
- Testing
- Gore® TAG® Thoracic Aortic Branch Stent Graft System
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- W.L.Gore & Associates
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Stroke, Cerebral Ischemia
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Trial name
- NCT00141011
- Testing
- Ancrod (Viprinex)
- Where
- 100 sites in United States, Australia and 8 more
- Volunteers
- 277 people
- Sponsor
- Neurobiological Technologies
Acute Coronary Syndrome (ACS)
Maintenance of Platelet Inhibition With Cangrelor
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
- Trial name
- Bridge (NCT00767507)
- Testing
- cangrelor
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- The Medicines Company
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients…
- Trial name
- NCT06577519
- Testing
- Vicagrel, Clopidogrel
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer
- Trial name
- NCT05153330
- Testing
- BMF-219
- Where
- 41 sites in United States, Greece and 3 more
- Volunteers
- 55 people
- Sponsor
- Biomea Fusion Inc.
Acute Coronary Syndromes
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status…
- Trial name
- NCT01611272
- Where
- 23 sites in South Korea
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction
Safety Study of AMI MultiStem® to Treat Heart Attacks
The purpose of this study is to determine if escalating doses of AMI MultiStem® delivered by catheter can safely be given to patients that have had a recent heart attack treated with stent implantation.
- Trial name
- NCT00677222
- Testing
- AMI MultiStem®
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Healios K.K.
Acute Heart Failure
Heart & Diabetes - Feasibility Study
The main purpose of this study is to validate an intensive protocol of insulin infusion and subsequent subcutaneous insulin administration with the support of continuous glucose monitoring, in addition to reference finger-stick…
- Trial name
- NCT00922402
- Testing
- Intensive insulin infusion
- Where
- 2 sites in Italy
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Stroke
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
Research topic. A clinical trial of Danhong injection in treating acute ischemic stroke . Research purpose. To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke by a randomized, double-blind…
- Trial name
- NCT02152280
- Testing
- Danhong Injection, Normal Saline
- Volunteers
- 320 people
- Sponsor
- Beijing Bozhiyin T&S Co., Ltd.
Ischemic Stroke, Acute Stroke
Continuous Dual Aspiration Technique With Zoom System for Stroke
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
- Trial name
- ADAPT 2 0 (NCT07491952)
- Testing
- Zoom System
- Where
- 25 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Acute Ischemic Stroke, AIS
A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke
Study Methods: The trial consists of two phases, both including a placebo control. Phase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set.
- Trial name
- NCT07628933
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells Injection
- Where
- China
- Volunteers
- 35 people
- Sponsor
- BOE Technology Group Co., Ltd.
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Cerebrovascular Stroke
Sub-Acute Stroke Rehabilitation With AMES
The AMES device is designed to produce functional cortical changes by:(1) assisting the subject as he/she attempts to move the limb (assisted movement) and (2) enhancing movement sensation by vibrating the muscles during movement…
- Trial name
- AMES (NCT00609115)
- Testing
- AMES device (test), AMES device (crossover)
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- AMES Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.